Detection of CD133 expression in U87 glioblastoma cells using a novel anti-CD133 monoclonal antibody.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Oncology Letters

• Publication date

  2015-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/OL.2015.3079PMID 26137114PMCID PMC4473606
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer.

  2014cited by this paper
• CD133 expression: a potential prognostic marker for non-small cell lung cancers

  2014cited by this paper
• Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer

  2013cited by this paper
• Emerging Biomarkers in Glioblastoma

  2013cited by this paper
• CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

  2012cited by this paper
• Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody.

  2011cited by this paper
• Insight into the complex regulation of CD133 in glioma

  2011cited by this paper
• Novel diagnostic and therapeutic approaches to malignant glioma.

  2011cited by this paper
• Inconsistent Immunohistochemical Expression Patterns of Four Different CD133 Antibody Clones in Glioblastoma

  2011cited by this paper
• Immunohistochemical Expression of Stem Cell, Endothelial Cell, and Chemosensitivity Markers in Primary Glioma Spheroids Cultured in Serum‐Containing and Serum‐Free Medium

  2010cited by this paper
• Retracted: Marker-independent identification of glioma-initiating cells

  2010cited by this paper
• Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.

  2010cited by this paper
• Limits of CD133 as a marker of glioma self‐renewing cells

  2009cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells

  2008cited by this paper
• CD133 identifies perivascular niches in grade II–IV astrocytomas

  2008cited by this paper
• Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas

  2008cited by this paper
• CD133 Expression and Cancer Stem Cells Predict Prognosis in High‐grade Oligodendroglial Tumors

  2008cited by this paper
• Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients

  2008cited by this paper
• The Stem Cell‐Associated Antigen CD133 (Prominin‐1) Is a Molecular Therapeutic Target for Metastatic Melanoma

  2008cited by this paper
• CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells

  2008cited by this paper
• Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme

  2008cited by this paper
• Persistence of CD133+ Cells in Human and Mouse Glioma Cell Lines: Detailed Characterization of GL261 Glioma Cells with Cancer Stem Cell-Like Properties

  2008cited by this paper
• CD133: molecule of the moment

  2008cited by this paper
• CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.

  2007cited by this paper
• Influence of oxygen tension on CD133 phenotype in human glioma cell cultures.

  2007cited by this paper
• Nomenclature of prominin-1 (CD133) splice variants - an update.

  2007cited by this paper
• Focus on molecules: prominin-1 (CD133).

  2007cited by this paper
• Cancer stem cells.

  2006cited by this paper
• AC133/CD133/Prominin-1.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Identification of human brain tumour initiating cells

  2004cited by this paper
• Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis

  2004cited by this paper
• Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer

  2004cited by this paper
• Identification of a cancer stem cell in human brain tumors.

  2003cited by this paper
• Estimation and projections of cancer prevalence from cancer registry data

  2002cited by this paper
• Stem cells, cancer, and cancer stem cells

  2001cited by this paper
• The Human AC133 Hematopoietic Stem Cell Antigen Is also Expressed in Epithelial Cells and Targeted to Plasma Membrane Protrusions*

  2000cited by this paper
• A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning.

  1997cited by this paper
• Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation.

  1996cited by this paper
• Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay.

  1989cited by this paper

• Lipid metabolism in cancer stem cells: reprogramming, mechanisms, crosstalk, and therapeutic approaches

  2025cites this paper
• Glioblastoma therapy: State of the field and future prospects.

  2024cites this paper
• The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection

  2024cites this paper
• Targeting tumor markers in ovarian cancer treatment.

  2024cites this paper
• Abnormal glycosylation in glioma: related changes in biology, biomarkers and targeted therapy

  2023cites this paper
• Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

  2023cites this paper
• Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells.

  2023cites this paper
• All-Trans Retinoic Acid Fosters the Multifarious U87MG Cell Line as a Model of Glioblastoma

  2021cites this paper
• PC3-secreted microprotein is expressed in glioblastoma stem-like cells and human glioma tissues.

  2021cites this paper
• Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance

  2021cites this paper
• An In-silico Approach and Experimental Analysis Combination: Two Strategies for Selecting the third Extracellular Domain (D-EC3) of Human CD133 Marker as a Target for Detection of Cancer Stem Cells

  2021cites this paper
• Design, Characterization, and Evaluation of scFvCD133/rGelonin: A CD133-Targeting Recombinant Immunotoxin for Use in Combination with Photochemical Internalization

  2019cites this paper
• Development a hyaluronic acid ion-pairing liposomal nanoparticle for enhancing anti-glioma efficacy by modulating glioma microenvironment

  2018cites this paper
• Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment

  2018cites this paper
• Evaluation of cancer stemness in breast cancer and glioblastoma spheroids in vitro

  2018cites this paper
• The Impact of Non-Lethal Single-Dose Radiation on Tumor Invasion and Cytoskeletal Properties

  2017cites this paper
• Establishment of CMab-43, a Sensitive and Specific Anti-CD133 Monoclonal Antibody, for Immunohistochemistry

  2017cites this paper
• Wnt/β-catenin signaling pathway inhibits the proliferation and apoptosis of U87 glioma cells via different mechanisms

  2017cites this paper
• Mechanisms of Resistance to TPCS2a-Photodynamic Therapy: Implication for Photochemical Internalization

  2017cites this paper
• Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response

  2017cites this paper
• Expression of recombinant human anti-TNF-α scFv-Fc in Arabidopsis thaliana seeds.

  2016cites this paper
• Liposomes Combined an Integrin αvβ3-Specific Vector with pH-Responsible Cell-Penetrating Property for Highly Effective Antiglioma Therapy through the Blood-Brain Barrier.

  2015cites this paper